CIS Biotech, Inc

Blood tests for the prediction and diagnosis of ischemic stroke

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Atlanta, GA, USA
  • Currency USD
  • Founded August 2000
  • Employees 8
  • Incorporation Type LLC
  • Website cisbiotech.com

Company Summary

CIS Biotech has developed the Gold Dot NR2 ELISA test kit for ischemic stroke prediction for export under the CE mark.

Term Sheet has been signed for licensing NR2 biomarker to DRD Ltd. (www.drdbiotech.ru), Skolkovo resident awarded mega-grant DRD Ltd. will market the CIS Biotech stroke test to the Eastern European market and the BRICS countries.

CIS will receive a License Fee of $1,000,000 in 2015-2016, along with royalty for 20 years.

Team

  • Uliana Danilenko

  • Galina Izykenova
    Secretary/Treasurer

    Ph.D. Biochemistry

  • Robert Rose Rhinehart
    President

    Bachelor of Electrical Engineering, Ga Tech
    Vice President (retired) Merrill Lynch
    Certified Financial Planner(Retired)

  • Robert Rhinehart

Advisors

  • Clark Sullivan, Arnall, Golden & Gregory
    Lawyer
    Unconfirmed
    Barnes, Broyles & Associates
    Accountant
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free